Intervention

AMG 706

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 5 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5

Recruiting0

Common conditions9

Lead sponsors shown1

Clinical trials

5 shown

MONET1-MOtesanib NSCLC Efficacy and Tolerability StudyNCT00460317 · 2007-07-01

TERMINATED

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLCNCT00369070 · 2007-01-31

TERMINATED

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast CancerNCT00356681 · 2006-12-01

TERMINATED

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast CancerNCT00322400 · 2006-03-01

COMPLETED

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced CancerNCT00101907 · 2004-12-01

TERMINATED

Common conditions

Locally Recurrent and Metastatic Breast Cancer2 Advanced Non-squamous NSCLC1 Breast Cancer1 Breast Neoplasms1 Breast Tumors1 Esophageal Cancer1 Lung Cancer1 Non-Small Cell Lung Cancer1 Pancreatic Cancer1

Leading sponsors

Amgen5

Trial status mix

TERMINATED4

COMPLETED1

Phase mix

PHASE12

PHASE22

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.